AU2009226956C1 - Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists - Google Patents

Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists Download PDF

Info

Publication number
AU2009226956C1
AU2009226956C1 AU2009226956A AU2009226956A AU2009226956C1 AU 2009226956 C1 AU2009226956 C1 AU 2009226956C1 AU 2009226956 A AU2009226956 A AU 2009226956A AU 2009226956 A AU2009226956 A AU 2009226956A AU 2009226956 C1 AU2009226956 C1 AU 2009226956C1
Authority
AU
Australia
Prior art keywords
compound
alkyl
mixture
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009226956A
Other languages
English (en)
Other versions
AU2009226956B2 (en
AU2009226956A1 (en
AU2009226956A8 (en
Inventor
Martin De Haan
Wouter I. Iwema Bakker
Cornelis G. Kruse
Agatha A.M. Rensink
Axel Stoit
Martina A.W. Van Der Neut
Arnold Van Loevezijn
Jennifer Venhorst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Bahamas Ltd
Original Assignee
AbbVie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Bahamas Ltd filed Critical AbbVie Bahamas Ltd
Publication of AU2009226956A1 publication Critical patent/AU2009226956A1/en
Publication of AU2009226956A8 publication Critical patent/AU2009226956A8/en
Application granted granted Critical
Publication of AU2009226956B2 publication Critical patent/AU2009226956B2/en
Assigned to ABBVIE BAHAMAS LTD. reassignment ABBVIE BAHAMAS LTD. Request for Assignment Assignors: ABBOTT HEALTHCARE PRODUCTS B.V.
Publication of AU2009226956C1 publication Critical patent/AU2009226956C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2009226956A 2008-03-18 2009-03-17 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists Ceased AU2009226956C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3746308P 2008-03-18 2008-03-18
EP08152873 2008-03-18
EP08152873.9 2008-03-18
US61/037,463 2008-03-18
PCT/EP2009/053133 WO2009115515A1 (en) 2008-03-18 2009-03-17 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists

Publications (4)

Publication Number Publication Date
AU2009226956A1 AU2009226956A1 (en) 2009-09-24
AU2009226956A8 AU2009226956A8 (en) 2010-09-23
AU2009226956B2 AU2009226956B2 (en) 2013-05-23
AU2009226956C1 true AU2009226956C1 (en) 2014-03-06

Family

ID=39639064

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009226956A Ceased AU2009226956C1 (en) 2008-03-18 2009-03-17 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists

Country Status (29)

Country Link
US (3) US8563723B2 (enExample)
EP (2) EP2265589B1 (enExample)
JP (1) JP5504252B2 (enExample)
KR (1) KR101623357B1 (enExample)
CN (2) CN102036967B (enExample)
AR (1) AR070898A1 (enExample)
AU (1) AU2009226956C1 (enExample)
BR (1) BRPI0908738A8 (enExample)
CA (1) CA2717922A1 (enExample)
CO (1) CO6290679A2 (enExample)
CR (1) CR11742A (enExample)
DK (2) DK2610247T3 (enExample)
DO (2) DOP2010000276A (enExample)
EA (1) EA023176B1 (enExample)
EC (1) ECSP10010476A (enExample)
ES (2) ES2565184T3 (enExample)
HK (1) HK1201823A1 (enExample)
IL (1) IL207846A0 (enExample)
MX (1) MX2010010299A (enExample)
MY (1) MY155318A (enExample)
NZ (1) NZ587743A (enExample)
PH (1) PH12013502376A1 (enExample)
PL (2) PL2265589T3 (enExample)
PT (1) PT2610247T (enExample)
SG (1) SG183688A1 (enExample)
TW (1) TWI557110B (enExample)
UA (1) UA105629C2 (enExample)
WO (1) WO2009115515A1 (enExample)
ZA (1) ZA201006272B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079935A1 (es) * 2010-01-29 2012-02-29 Abbott Healthcare Products Bv Sintesis de derivados de pirazolin carboxamidina sustituida
AU2012296639B2 (en) * 2011-08-15 2016-06-09 University Of Utah Research Foundation Substituted (E)-N'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors
CN104903296A (zh) 2012-11-16 2015-09-09 百时美施贵宝公司 二氢吡唑gpr40调节剂
AR104762A1 (es) 2012-11-16 2017-08-16 Bristol Myers Squibb Co Moduladores de dihidropirazol gpr40
UY35143A (es) * 2012-11-16 2014-05-30 Bristol Myers Squibb Co Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g
WO2015172059A1 (en) * 2014-05-09 2015-11-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Pyrazole derivatives and their use as cannabinoid receptor mediators
CA2957566C (en) 2014-08-12 2023-08-01 Daniel Paul Becker Indoline sulfonamide inhibitors of dape and ndm-1 and use of the same
EP3109237A1 (en) * 2015-06-22 2016-12-28 AnaMar AB Novel 5-ht2 antagonists
CN107460160A (zh) * 2017-08-23 2017-12-12 世贸天阶制药（江苏）有限责任公司 一种cho细胞无血清培养基
US10879709B2 (en) 2018-05-31 2020-12-29 National Taipei University Of Technology Power management system and operating method thereof
CN117567338A (zh) 2019-10-09 2024-02-20 拜耳公司 作为农药的新的杂芳基三唑化合物
CA3185968A1 (en) 2020-07-13 2022-01-20 Tony Lahoutte Antibody fragment against folr1
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008034863A2 (en) * 2006-09-22 2008-03-27 Solvay Pharmaceuticals B.V. Sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100950430B1 (ko) * 2001-09-21 2010-04-02 솔베이 파마슈티칼스 비. 브이 효력있는 ｃｂ1-길항 작용을 가지는4,5-디하이드로-1ｈ-피라졸 유도체
GB0422263D0 (en) * 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008034863A2 (en) * 2006-09-22 2008-03-27 Solvay Pharmaceuticals B.V. Sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists
US7728018B2 (en) * 2006-09-22 2010-06-01 Solvay Pharmaceuticals B.V. Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-HT6 antagonists

Also Published As

Publication number Publication date
EP2265589B1 (en) 2016-01-27
KR101623357B1 (ko) 2016-05-23
HK1201823A1 (en) 2015-09-11
ES2577867T3 (es) 2016-07-19
HK1152708A1 (en) 2012-03-09
EP2265589A1 (en) 2010-12-29
US8901108B2 (en) 2014-12-02
TWI557110B (zh) 2016-11-11
AU2009226956B2 (en) 2013-05-23
DK2610247T3 (en) 2016-06-13
MY155318A (en) 2015-09-30
US8563723B2 (en) 2013-10-22
PL2610247T3 (pl) 2017-02-28
BRPI0908738A8 (pt) 2017-10-10
ZA201006272B (en) 2011-05-25
KR20100136504A (ko) 2010-12-28
PT2610247T (pt) 2016-07-07
SG183688A1 (en) 2012-09-27
ES2565184T3 (es) 2016-04-01
EA023176B1 (ru) 2016-05-31
JP2011517443A (ja) 2011-06-09
CN102036967A (zh) 2011-04-27
AU2009226956A1 (en) 2009-09-24
TW200942519A (en) 2009-10-16
CO6290679A2 (es) 2011-06-20
PH12013502376B1 (en) 2015-01-12
PH12013502376A1 (en) 2015-01-12
IL207846A0 (en) 2010-12-30
WO2009115515A1 (en) 2009-09-24
CR11742A (es) 2011-03-03
US20150051239A1 (en) 2015-02-19
DOP2010000277A (es) 2011-01-31
DOP2010000276A (es) 2010-11-15
JP5504252B2 (ja) 2014-05-28
EP2610247A1 (en) 2013-07-03
CN102036967B (zh) 2014-10-15
AU2009226956A8 (en) 2010-09-23
MX2010010299A (es) 2010-12-15
EP2610247B1 (en) 2016-05-25
DK2265589T3 (en) 2016-03-21
BRPI0908738A2 (pt) 2017-06-13
NZ587743A (en) 2012-06-29
US9126942B2 (en) 2015-09-08
US20110046171A1 (en) 2011-02-24
PL2265589T3 (pl) 2016-06-30
AR070898A1 (es) 2010-05-12
CN104003937A (zh) 2014-08-27
EA201071083A1 (ru) 2011-04-29
ECSP10010476A (es) 2010-10-30
US20140011775A1 (en) 2014-01-09
UA105629C2 (uk) 2014-06-10
CA2717922A1 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
AU2009226956B2 (en) Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists
AU2007298987B2 (en) Sulfonylpyrazoline carboxamidine derivatives as 5-HT6 antagonists
US20080318941A1 (en) 4' substituted compounds having 5-ht6 receptor affinity
US20100029629A1 (en) Acyclic compounds having 5-ht6 receptor affinity
MX2015000056A (es) Derivados de imidazo[2,1b]tiazol, su preparación y su uso como medicamentos.
CN104254535B (zh) 取代的吡唑并[1,5‑a]吡啶、其制备及作为药物的应用
HK1152708B (en) Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists
JP2026511081A (ja) Ａｔｍキナーゼ阻害剤
HK1210149B (en) Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 24, NO 36, PAGE(S) 4200 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME SOLVAY PHARMACEUTICALS B.V., APPLICATION NO. 2009226956, UNDER INID (71) CORRECT THE APPLICANT NAME TO READ ABBOTT HEALTHCARE PRODUCTS B.V.

TH Corrigenda

Free format text: IN VOL 24 , NO 36 , PAGE(S) 4200 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ABBOTT HEALTHCARE PRODUCTS B.V., APPLICATION NO. 2009226956, UNDER INID (54) CORRECT THE TITLE TO READ ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 AUG 2013 .

PC1 Assignment before grant (sect. 113)

Owner name: ABBVIE BAHAMAS LTD.

Free format text: FORMER APPLICANT(S): ABBOTT HEALTHCARE PRODUCTS B.V.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 AUG 2013

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired